Microbix Biosystems (TSE:MBX) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

Posted by Jeff Wilder on Aug 12th, 2026

Microbix Biosystems Inc. (TSE:MBX – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$0.30 and traded as high as C$0.31. Microbix Biosystems shares last traded at C$0.30, with a volume of 31,511 shares trading hands.

Microbix Biosystems Trading Up 3.2%

The business’s 50-day moving average is C$0.30 and its two-hundred day moving average is C$0.26. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The stock has a market capitalization of C$44.00 million, a PE ratio of -7.80 and a beta of 0.72.

Microbix Biosystems (TSE:MBX – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$3.38 million during the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. On average, analysts predict that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

Insider Activity at Microbix Biosystems

In related news, Director Martin Marino purchased 115,000 shares of Microbix Biosystems stock in a transaction that occurred on Thursday, May 28th. The shares were purchased at an average cost of C$0.28 per share, with a total value of C$32,200.00. Following the transaction, the director owned 2,000,167 shares of the company’s stock, valued at approximately C$560,046.76. The trade was a 6.10% increase in their position. In the last quarter, insiders bought 251,000 shares of company stock worth $68,355. Company insiders own 14.00% of the company’s stock.

About Microbix Biosystems

(Get Free Report)

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.